Literature DB >> 23634377

Personalized medicine: The return of the house call?

Gary R Cutter1, Yuliang Liu.   

Abstract

Personalized medicine is a new mantra evolving in health care. Harnessing each person's clinical, genetic, genomic, and environmental information drives the concept. The idea is simple. We can maximize a patient's chances of a better outcome if we base treatments on what we know. However, isn't this in many ways the way it's always been? Isn't this in part the basis for that old-time house call? To see how a disease or condition is being cared for in the home environment? Clinicians have long used personalized medicine, without overt use of single nucleotide polymorphisms, but certainly not totally void of genetic information. Of course, physicians of the past did not have gene chips, but they did have family histories often informing their decisions. Today as we raise the hopes for targeted therapies to break us free from the algorithmic treatments often followed by hit and miss approaches, there is a renewed fervor for personalized medicine. How do we get there and how does the average clinician or researcher understand the burgeoning array of information, talking heads, and latest hype of subgroup benefits? A key aspect is to trust your training, your experience, and your instincts, coupled with a few repeated doses of biostatistics.

Entities:  

Year:  2012        PMID: 23634377      PMCID: PMC3613206          DOI: 10.1212/CPJ.0b013e318278c328

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  11 in total

1.  The predictive value of microbiologic diagnostic tests if asymptomatic carriers are present.

Authors:  Ronny K Gunnarsson; Jan Lanke
Journal:  Stat Med       Date:  2002-06-30       Impact factor: 2.373

2.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

3.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

4.  Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

Authors:  S E Bushnell; Z Zhao; C C Stebbins; D Cadavid; A M Buko; E T Whalley; J A Davis; E M Versage; J R Richert; R C Axtell; L Steinman; R Medori
Journal:  Neurology       Date:  2012-05-09       Impact factor: 9.910

5.  The elusive biomarker for personalized medicine in multiple sclerosis: the search continues.

Authors:  Richard A Rudick
Journal:  Neurology       Date:  2012-05-09       Impact factor: 9.910

6.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

Authors:  Robert S Epstein; Thomas P Moyer; Ronald E Aubert; Dennis J O Kane; Fang Xia; Robert R Verbrugge; Brian F Gage; J Russell Teagarden
Journal:  J Am Coll Cardiol       Date:  2010-04-08       Impact factor: 24.094

7.  Diagnostic tests 2: Predictive values.

Authors:  D G Altman; J M Bland
Journal:  BMJ       Date:  1994-07-09

8.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.

Authors:  Mark A Hlatky; Philip Greenland; Donna K Arnett; Christie M Ballantyne; Michael H Criqui; Mitchell S V Elkind; Alan S Go; Frank E Harrell; Yuling Hong; Barbara V Howard; Virginia J Howard; Priscilla Y Hsue; Christopher M Kramer; Joseph P McConnell; Sharon-Lise T Normand; Christopher J O'Donnell; Sidney C Smith; Peter W F Wilson
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

Review 10.  APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease.

Authors:  Xuemei Huang; Peter C Chen; Charles Poole
Journal:  Neurology       Date:  2004-06-22       Impact factor: 9.910

View more
  4 in total

Review 1.  Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review.

Authors:  Mubashir Hassan; Faryal Mehwish Awan; Anam Naz; Enrique J deAndrés-Galiana; Oscar Alvarez; Ana Cernea; Lucas Fernández-Brillet; Juan Luis Fernández-Martínez; Andrzej Kloczkowski
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

2.  Marine Exopolysaccharide Complexed With Scandium Aimed as Theranostic Agents.

Authors:  Mattia Mazza; Cyrille Alliot; Corinne Sinquin; Sylvia Colliec-Jouault; Pascal E Reiller; Sandrine Huclier-Markai
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

3.  Predicting chemosensitivity using drug perturbed gene dynamics.

Authors:  Joshua D Mannheimer; Ashok Prasad; Daniel L Gustafson
Journal:  BMC Bioinformatics       Date:  2021-01-07       Impact factor: 3.169

4.  Antiproliferative Properties of Scandium Exopolysaccharide Complexes on Several Cancer Cell Lines.

Authors:  Javier Muñoz-Garcia; Mattia Mazza; Cyrille Alliot; Corinne Sinquin; Sylvia Colliec-Jouault; Dominique Heymann; Sandrine Huclier-Markai
Journal:  Mar Drugs       Date:  2021-03-23       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.